Regeneron Says FDA Has Put Its New Pain Drug on Clinical Hold

Regeneron Pharmaceuticals Inc. Dec. 27, 2010, said in a Securities and Exchange Commission filing that the Food and Drug Administration has placed its investigational pain drug on clinical hold after receiving a report of an adverse event in another company’s trial.

The drug, REGN475/SAR164877, is an anti-nerve growth factor (NGF) inhibitor, according to the filing.

FDA put the drug on clinical hold because of a confirmed case of avascular necrosis of a joint that was seen in another company’s anti-nerve growth factor program, the Tarrytown, N.Y.-based company said. Avascular necrosis is a disease where there is cellular death of bone ...